-transparent.png){kind=logo}
The lupus anticoagulant, with or without other symptoms or signs of lupus, has been described in patients taking procainamide. Screening all such patients for the presence of these anticoagulants may be warranted (despite the rarity of episodes of bleeding) in view of the potentially increased risk of thrombotic events in patients who may already be predisposed. A prospective study to determine the incidence of lupus anticoagulant in procainamide-treated patients and the true frequency of thrombosis in these patients would be helpful in determining appropriate management.
Related Publications
M R Heyman, and
R H Flores, and
B B Edelman, and
N H Carliner
September 1988,
Wisconsin medical journal,
M R Heyman, and
R H Flores, and
B B Edelman, and
N H Carliner
September 1982,
La Nouvelle presse medicale,
M R Heyman, and
R H Flores, and
B B Edelman, and
N H Carliner
January 1989,
Acta haematologica,
M R Heyman, and
R H Flores, and
B B Edelman, and
N H Carliner
February 1995,
American journal of hematology,
M R Heyman, and
R H Flores, and
B B Edelman, and
N H Carliner
October 1977,
Archives of internal medicine,
M R Heyman, and
R H Flores, and
B B Edelman, and
N H Carliner
March 1996,
The Annals of thoracic surgery,
M R Heyman, and
R H Flores, and
B B Edelman, and
N H Carliner
November 1981,
Archives of internal medicine,
M R Heyman, and
R H Flores, and
B B Edelman, and
N H Carliner
June 1976,
The Johns Hopkins medical journal,
M R Heyman, and
R H Flores, and
B B Edelman, and
N H Carliner
March 1974,
South Dakota journal of medicine,
M R Heyman, and
R H Flores, and
B B Edelman, and
N H Carliner
June 1968,
Arizona medicine,
